Frequently Asked Questions
A clinical trial is a research study that examines how well a potential therapy works in humans.
Qualified doctors, nurses and other medical professionals conduct the study. Clinical trials are performed according to government regulations, which help protect the safety and rights of participants.
New medications can only be developed through the process of clinical trials.
Many relapsed or refractory AML patients today are not eligible for potentially curative bone marrow transplant because of their health status or they have active disease and are unable to get into remission with chemotherapy.
The SIERRA trial does not require a patient to be in remission to potentially get a bone marrow transplant and is investigating the use of 131I apamistamab (Iomab-B) in patients age 55 and older with active, relapsed or refractory Acute Myeloid Leukemia (AML).
The purpose of this study is to determine whether 131I apamistamab (Iomab-B) will help make the stem cell transplant procedure safer, and whether this is a better treatment approach compared to current treatment options.
SIERRA may be an option for you.
This clinical trial has certain criteria that a person with relapsed or refractory AML has to meet to determine if they can participate. After you have discussed the trial with your doctor, specific tests will be done to see if you qualify for this study. Please click here to download/print details of the SIERRA Trial to review with your doctor.
Actinium Pharmaceuticals is sponsoring this multi-center clinical trial.
The total number of AML patients enrolled in this clinical trial will be approximately 150. Your doctor can provide additional details about the SIERRA Trial. Please click here to download/print details of the SIERRA Trial to review with your doctor.
Visit our contact a study location page to see the list of participating sites.